These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1815070)

  • 21. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.
    Kuze J; Mutoh T; Takenaka T; Oda N; Hanioka N; Narimatsu S
    Xenobiotica; 2013 Jul; 43(7):598-606. PubMed ID: 23282066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In situ nasal absorption of midazolam in rats.
    Olivier JC; Djilani M; Fahmy S; Couet W
    Int J Pharm; 2001 Feb; 213(1-2):187-92. PubMed ID: 11165106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral mucosal absorption of midazolam in dogs is strongly pH dependent.
    Zhang J; Niu S; Zhang H; Streisand JB
    J Pharm Sci; 2002 Apr; 91(4):980-2. PubMed ID: 11948536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers.
    Fujii J; Inotsume N; Nakano M
    J Pharmacobiodyn; 1988 Mar; 11(3):206-9. PubMed ID: 3411438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration.
    Rey E; Delaunay L; Pons G; Murat I; Richard MO; Saint-Maurice C; Olive G
    Eur J Clin Pharmacol; 1991; 41(4):355-7. PubMed ID: 1804652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of single-dose hypnotic treatment before elective operation.
    Keighley MR; Gannon M; Warlow J; Jenkins CR; Gammon RJ
    Br Med J; 1980 Sep; 281(6244):829-31. PubMed ID: 6107159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
    Wermeling DP; Record KA; Archer SM; Rudy AC
    Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential.
    Fukuta O; Braham RL; Yanase H; Kurosu K
    ASDC J Dent Child; 1997; 64(2):89-98. PubMed ID: 9188997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal absorption of procyclidine in rats and dogs.
    Jang EJ; Lee YJ; Chung SJ; Shim CK
    Arch Pharm Res; 2001 Jun; 24(3):219-23. PubMed ID: 11440081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-alpha] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys.
    Kitagawa H; Esumi Y; Kurosawa S; Sekine S; Yokoshima T
    Xenobiotica; 1979 Jul; 9(7):415-28. PubMed ID: 40350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.
    Pelser A; Müller DG; du Plessis J; du Preez JL; Goosen C
    Biopharm Drug Dispos; 2002 Sep; 23(6):239-44. PubMed ID: 12214324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.
    Yuan R; Flockhart DA; Balian JD
    J Clin Pharmacol; 1999 Nov; 39(11):1109-25. PubMed ID: 10579141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and CSF entry of flurazepam in dogs.
    Ochs HR; Greenblatt DJ; Burstein ES; Eichelkraut W; Hahn N
    Pharmacology; 1988; 36(3):166-71. PubMed ID: 3368503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the dose equivalence of flurazepam and triazolam.
    Gorenstein C; Gentil V; Ragazzo PC; Manzano G; Arruda PV; Peres CA
    Braz J Med Biol Res; 1986; 19(2):173-82. PubMed ID: 3828570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methodology for demonstrating sustained efficacy of hypnotics: a comparative study of triazolam and flurazepam.
    Sundaresan PR; Wardell WM; Weintraub M; Lasagna L
    Clin Pharmacol Ther; 1979 Apr; 25(4):391-8. PubMed ID: 34496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration.
    Smith RB; Kroboth PD; Phillips JP
    J Clin Pharmacol; 1986 Feb; 26(2):120-4. PubMed ID: 3950055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of next-day anterograde amnesia caused by flurazepam hydrochloride and triazolam.
    Juhl RP; Daugherty VM; Kroboth PD
    Clin Pharm; 1984; 3(6):622-5. PubMed ID: 6150782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daytime carryover of triazolam and flurazepam in elderly insomniacs.
    Carskadon MA; Seidel WF; Greenblatt DJ; Dement WC
    Sleep; 1982; 5(4):361-71. PubMed ID: 6131526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination.
    Lacoste L; Bouquet S; Ingrand P; Caritez JC; Carretier M; Debaene B
    Lab Anim; 2000 Jan; 34(1):29-35. PubMed ID: 10759364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.